Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Mol Cancer Res. 2020 Nov 5;19(2):249–260. doi: 10.1158/1541-7786.MCR-20-0466

Figure 2.

Figure 2.

Prognostic effects of TP53 mutation (Mut-TP53) and p53 overexpression (p53high) in patients with MYC rearrangement (MYC-R). A, Patients with DLBCL with concurrent MYC-R and p53high displayed poor OS and PFS but showed little additive negative effect to that of single MYC-R or p53high abnormality. B, Concurrent Mut-TP53 and MYC-R synergistically worsened the OS and PFS in DLBCL. C and D, TP53 mutation had significantly adverse impact independent of MYC-R status.